Abstract
Interventional oncology represents a relatively new clinical discipline based upon minimally invasive therapies applicable to almost every human organ and disease. Over the last several decades, rapidly evolving research developments have introduced a newer generation of treatment devices, reagents, and image-guidance systems to expand the armamentarium of interventional oncology across a wide spectrum of disease sites, offering potential cure, control, or palliative care for many types of cancer patients. Due to the widespread use of locoregional procedures, a comprehensive review of the methodologic and technical considerations to optimize patient selection with the aim of performing a safe procedure is mandatory. This article summarizes the expert discussion and report from the Mediterranean Interventional Oncology Live Congress (MIOLive 2020) held in Rome, Italy, integrating evidence-reported literature and experience-based perceptions as a means for providing guidance on prudent ways to reduce complications. The aim of the paper is to provide an updated guiding tool not only to residents and fellows but also to colleagues approaching locoregional treatments.
Highlights
The Latin aphorism “primum non nocere”, meaning “first, do no harm”, most often attributed to Hippocrates of Kos himself, is one of the principal precepts guiding all medical interventions
As wisely underlined by Sokol, even if a literal reading of the expression would lead clinicians to do nothing at all, a more applicable formulation should be “primum non plus nocere quam succurrere”, that is “first do no net harm”. Clinicians must balance their primary obligation to benefit the patient against their obligation not to cause harm [1]. It is from this perspective that this concept must be strictly applied in interventional oncology, a relatively new clinical discipline based on minimally invasive therapies treating almost every human organ and solid cancer type
Over the last several decades, rapidly evolving research developments have introduced a newer generation of treatment devices, reagents, and image-guidance systems to expand the armamentarium of interventional oncology across a wide spectrum of disease sites offering potential cure, control, or palliative care for many types of cancer patients [2,3,4,5]
Summary
The Latin aphorism “primum non nocere”, meaning “first, do no harm”, most often attributed to Hippocrates of Kos himself, is one of the principal precepts guiding all medical interventions. As wisely underlined by Sokol, even if a literal reading of the expression would lead clinicians to do nothing at all, a more applicable formulation should be “primum non plus nocere quam succurrere”, that is “first do no net harm” For achieving this aim, clinicians must balance their primary obligation to benefit the patient against their obligation not to cause harm [1]. Clinicians must balance their primary obligation to benefit the patient against their obligation not to cause harm [1] It is from this perspective that this concept must be strictly applied in interventional oncology, a relatively new clinical discipline based on minimally invasive therapies treating almost every human organ and solid cancer type. Our goal is to assist residents and fellows who are training in interventional radiology, and practicing colleagues who are gaining greater familiarity with percutaneous or intra-arterial treatments
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
